Nonoperating Income (Expense) in USD of Freeline Therapeutics Holdings plc from 2019 to Q1 2023

Taxonomy & unit: us-gaap: USD
Description: The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary: Freeline Therapeutics Holdings plc quarterly/annual Nonoperating Income (Expense) history and change rate from 2019 to Q1 2023.
Freeline Therapeutics Holdings plc Nonoperating Income (Expense) for the quarter ending March 31, 2023 was $21.4M, a 1366% increase year-over-year.
Freeline Therapeutics Holdings plc annual Nonoperating Income (Expense) for 2022 was $9.84M, a 322% increase from 2021.
Freeline Therapeutics Holdings plc annual Nonoperating Income (Expense) for 2021 was $2.33M, a 62.8% decline from 2020.
Freeline Therapeutics Holdings plc annual Nonoperating Income (Expense) for 2020 was $6.26M, a 36.7% decline from 2019.

Nonoperating Income (Expense), Quarterly (USD)

Nonoperating Income (Expense), YoY Quarterly Change (%)

Nonoperating Income (Expense), Annual (USD)

Nonoperating Income (Expense), YoY Annual Change (%)

Freeline Therapeutics Holdings plc Quarterly Nonoperating Income (Expense) (USD)

Period	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed
Q1 2023	$21.4M	+$20M	+1366%	Jan 1, 2023	Mar 31, 2023	6-K	2023-05-30
Q1 2022	$1.46M	+$2.46M		Jan 1, 2022	Mar 31, 2022	6-K	2023-05-30
Q1 2021	-$995K	-$5.61M	-122%	Jan 1, 2021	Mar 31, 2021	6-K	2022-05-10
Q1 2020	$4.62M			Jan 1, 2020	Mar 31, 2020	6-K	2021-05-17

Period	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed
2022	$9.84M	+$7.51M	+322%	Jan 1, 2022	Dec 31, 2022	20-F	2023-04-04
2021	$2.33M	-$3.93M	-62.8%	Jan 1, 2021	Dec 31, 2021	20-F	2023-04-04
2020	$6.26M	-$3.62M	-36.7%	Jan 1, 2020	Dec 31, 2020	20-F	2023-04-04
2019	$9.88M			Jan 1, 2019	Dec 31, 2019	20-F	2022-03-31

* An asterisk sign (*) next to the value indicates that the value is likely invalid.